Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, 10x Genomics to Develop 'Premium' Exome

NEW YORK (GenomeWeb) – Agilent Technologies and 10x Genomics announced today that they are collaborating on a plan to develop a "premium" exome — essentially, that they are combining some of their complementary products to allow users to research exomes in depth, including previously unmappable loci and structural variation.

The companies will create products using Agilent's SureSelect target enrichment technology on 10x's Chromium molecular barcoding and analysis platform, which generates linked-read data from inputs of approximately one nanogram of DNA.

The combination products can be used for coverage and variant calling, including in hard-to-map regions of the genome, the companies said. Importantly, they will include both exonic targets and additional loci to enhance phasing, thereby providing users with more insight into complex genomic structural anomalies.

"Our collaboration with 10x Genomics will advance the understanding of underlying causes of disease, and we are excited to be at the forefront of this innovation," Herman Verrelst, VP and general manager of Agilent's genomics division, said in a statement. "Its unique potential to resolve maternal and paternal haplotypes and the ability to detect structural variants, such as translocations, will make a significant impact on clinical research for constitutional diseases and cancer."

The deal was announced a day after 10x said it has struck sequencing partnerships with Qiagen and Illumina.